← All trials
NCT05694611
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2023
- Primary completion
- Jul 31, 2029
- Completion date
- Dec 31, 2029
- First posted
- Jan 23, 2023
- Last posted
- Apr 25, 2023
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TurkuLead sponsor
- University of TurkuOverall official - principal investigator
- University of TurkuReponsible party - principal investigator
- University of TurkuStudy chair
- University of TurkuStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.